Literature DB >> 22431598

Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity.

Till Maurer1, Lindsay S Garrenton, Angela Oh, Keith Pitts, Daniel J Anderson, Nicholas J Skelton, Benjamin P Fauber, Borlan Pan, Shiva Malek, David Stokoe, Mary J C Ludlam, Krista K Bowman, Jiansheng Wu, Anthony M Giannetti, Melissa A Starovasnik, Ira Mellman, Peter K Jackson, Joachim Rudolph, Weiru Wang, Guowei Fang.   

Abstract

The Ras gene is frequently mutated in cancer, and mutant Ras drives tumorigenesis. Although Ras is a central oncogene, small molecules that bind to Ras in a well-defined manner and exert inhibitory effects have not been uncovered to date. Through an NMR-based fragment screen, we identified a group of small molecules that all bind to a common site on Ras. High-resolution cocrystal structures delineated a unique ligand-binding pocket on the Ras protein that is adjacent to the switch I/II regions and can be expanded upon compound binding. Structure analysis predicts that compound-binding interferes with the Ras/SOS interactions. Indeed, selected compounds inhibit SOS-mediated nucleotide exchange and prevent Ras activation by blocking the formation of intermediates of the exchange reaction. The discovery of a small-molecule binding pocket on Ras with functional significance provides a new direction in the search of therapeutically effective inhibitors of the Ras oncoprotein.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22431598      PMCID: PMC3325706          DOI: 10.1073/pnas.1116510109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway.

Authors:  Herbert Waldmann; Ioanna-Maria Karaguni; Mercedes Carpintero; Eleni Gourzoulidou; Christian Herrmann; Christoph Brockmann; Hartmut Oschkinat; Oliver Müller
Journal:  Angew Chem Int Ed Engl       Date:  2004-01-16       Impact factor: 15.336

2.  Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins.

Authors:  M V Milburn; L Tong; A M deVos; A Brünger; Z Yamaizumi; S Nishimura; S H Kim
Journal:  Science       Date:  1990-02-23       Impact factor: 47.728

3.  Detection and structural characterization of ras oncoprotein-inhibitors complexes by electrospray mass spectrometry.

Authors:  A K Ganguly; B N Pramanik; E C Huang; S Liberles; L Heimark; Y H Liu; A Tsarbopoulos; R J Doll; A G Taveras; S Remiszewski; M E Snow; Y S Wang; B Vibulbhan; D Cesarz; J E Brown; J del Rosario; L James; P Kirschmeier; V Girijavallabhan
Journal:  Bioorg Med Chem       Date:  1997-05       Impact factor: 3.641

4.  Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex.

Authors:  A G Taveras; S W Remiszewski; R J Doll; D Cesarz; E C Huang; P Kirschmeier; B N Pramanik; M E Snow; Y S Wang; J D del Rosario; B Vibulbhan; B B Bauer; J E Brown; D Carr; J Catino; C A Evans; V Girijavallabhan; L Heimark; L James; S Liberles; C Nash; L Perkins; M M Senior; A Tsarbopoulos; S E Webber
Journal:  Bioorg Med Chem       Date:  1997-01       Impact factor: 3.641

5.  The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.

Authors:  K Scheffzek; M R Ahmadian; W Kabsch; L Wiesmüller; A Lautwein; F Schmitz; A Wittinghofer
Journal:  Science       Date:  1997-07-18       Impact factor: 47.728

6.  Analysis of intrinsic and CDC25-stimulated guanine nucleotide exchange of p21ras-nucleotide complexes by fluorescence measurements.

Authors:  C Lenzen; R H Cool; A Wittinghofer
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

7.  Pseudomonas aeruginosa exoenzyme S ADP-ribosylates Ras at multiple sites.

Authors:  A K Ganesan; D W Frank; R P Misra; G Schmidt; J T Barbieri
Journal:  J Biol Chem       Date:  1998-03-27       Impact factor: 5.157

Review 8.  Hyperactive Ras in developmental disorders and cancer.

Authors:  Suzanne Schubbert; Kevin Shannon; Gideon Bollag
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

9.  A Ras-induced conformational switch in the Ras activator Son of sevenless.

Authors:  Tanya S Freedman; Holger Sondermann; Gregory D Friedland; Tanja Kortemme; Dafna Bar-Sagi; Susan Marqusee; John Kuriyan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

10.  The structural basis of the activation of Ras by Sos.

Authors:  P A Boriack-Sjodin; S M Margarit; D Bar-Sagi; J Kuriyan
Journal:  Nature       Date:  1998-07-23       Impact factor: 49.962

View more
  235 in total

1.  Regulation of RAS oncogenicity by acetylation.

Authors:  Moon Hee Yang; Seth Nickerson; Eric T Kim; Caroline Liot; Gaelle Laurent; Robert Spang; Mark R Philips; Yibing Shan; David E Shaw; Dafna Bar-Sagi; Marcia C Haigis; Kevin M Haigis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

Review 2.  How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.

Authors:  Ethan J Brock; Kyungmin Ji; John J Reiners; Raymond R Mattingly
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

Review 3.  RAS-targeted therapies: is the undruggable drugged?

Authors:  Amanda R Moore; Scott C Rosenberg; Frank McCormick; Shiva Malek
Journal:  Nat Rev Drug Discov       Date:  2020-06-11       Impact factor: 84.694

Review 4.  KRAS as a Therapeutic Target.

Authors:  Frank McCormick
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

5.  A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems.

Authors:  Arsheed A Ganaie; Hifzur R Siddique; Ishfaq A Sheikh; Aijaz Parray; Lei Wang; Jayanth Panyam; Peter W Villalta; Yibin Deng; Badrinath R Konety; Mohammad Saleem
Journal:  Mol Carcinog       Date:  2020-04-15       Impact factor: 4.784

6.  Human melanoma inhibitory protein binds to the FN12-14 Hep II domain of fibronectin.

Authors:  King Tuo Yip; Xueyin Zhong; Nadia Seibel; Oliver Arnolds; Miriam Schöpel; Raphael Stoll
Journal:  Biointerphases       Date:  2017-05-31       Impact factor: 2.456

7.  Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange.

Authors:  Michael C Burns; Qi Sun; R Nathan Daniels; DeMarco Camper; J Phillip Kennedy; Jason Phan; Edward T Olejniczak; Taekyu Lee; Alex G Waterson; Olivia W Rossanese; Stephen W Fesik
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

8.  Inhibition of Ras-Effector Interaction by Cyclic Peptides.

Authors:  Xianghong Wu; Punit Upadhyaya; Miguel A Villalona-Calero; Roger Briesewitz; Dehua Pei
Journal:  Medchemcomm       Date:  2013-02-01       Impact factor: 3.597

9.  Oncogenic K-Ras Binds to an Anionic Membrane in Two Distinct Orientations: A Molecular Dynamics Analysis.

Authors:  Priyanka Prakash; Yong Zhou; Hong Liang; John F Hancock; Alemayehu A Gorfe
Journal:  Biophys J       Date:  2016-03-08       Impact factor: 4.033

10.  Overview of simulation studies on the enzymatic activity and conformational dynamics of the GTPase Ras.

Authors:  Priyanka Prakash; Alemayehu A Gorfe
Journal:  Mol Simul       Date:  2014-03-19       Impact factor: 2.178

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.